Please use this identifier to cite or link to this item:
|Title:||Immunogenicity of a candidate DNA vaccine based on the prM/E genes of a dengue type 2 virus cosmopolitan genotype strain|
|Authors:||Dwi Hilda Putri|
Tjahjani Mirawati Sudiro
Ungke Anton Jaya
Beti Ernawati Dewi
Kobe University School of Medicine
|Citation:||Japanese Journal of Infectious Diseases. Vol.68, No.5 (2015), 357-363|
|Abstract:||© 2015, National Institute of Health. All rights reserved. The development of a dengue virus vaccine is a major priority in efforts to control the diseases. Several researchers are currently using the Asian 1 and Asian 2 genotypes as vaccine candidates for dengue type 2 virus (DENV-2). However, in this study, we constructed a recombinant plasmid-based prM/E gene, from a DENV-2 Cosmopolitan genotype strain as a dengue DNA vaccine candidate. The protein expression of the recombinant plasmid in CHO cells was analyzed using an enzyme-linked immunosorbent assay, western blotting, and sucrose gradient sedimentation. After being used to immunize ddY mice three times at doses of 25 or 100 μg, the DNA vaccine induced humoral immune responses. There was no difference in the neutralizing antibody titer (focus reduction neutralization test 50z value) of mice immunized with 25 and 100 μg DNA vaccine doses. When challenged with 3 × 10<sup>5</sup> FFU DENV-2, immunized mice could raise anamnestic neutralizing antibody responses, which were observed at day 4 and day 8 post-challenge. Analysis of immunogenicity using BALB/c mice showed that their antibody neutralization titers were lower than those of ddY mice. In addition, the antibodies produced after immunization and challenge could also neutralize a DENV-2 Asian 2 genotype (New Guinea C) strain. Therefore, the DENV-2 Cosmopolitan genotype may be a DENV-2 vaccine candidate.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.